IDELVION
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- IDELVION
- Generic name
- COAGULATION FACTOR IX RECOMBINANT HUMAN
- Manufacturer
- CSL Behring Lengnau AG
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- f74301bf-95e2-44ab-a8b6-98aa07b04683
- SPL ID
- fc29c907-a767-4a0e-b077-8c197e7ce8b3
- Version
- 12
- Effective date
- 2023-06-30
- Source export date
- 2026-11-13
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:33:15
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125582 | derived:openfda.application_number |
| application number | BLA125582 | openfda.application_number | |
| brand name | IDELVION | openfda.brand_name | |
| generic name | COAGULATION FACTOR IX RECOMBINANT HUMAN | openfda.generic_name | |
| manufacturer name | CSL Behring Lengnau AG | openfda.manufacturer_name | |
| ndc | package | 69911-869-02 | openfda.package_ndc |
| ndc | package | 69911-875-01 | openfda.package_ndc |
| ndc | package | 69911-876-01 | openfda.package_ndc |
| ndc | package | 69911-867-02 | openfda.package_ndc |
| ndc | package | 69911-866-02 | openfda.package_ndc |
| ndc | package | 69911-877-01 | openfda.package_ndc |
| ndc | package | 69911-865-02 | openfda.package_ndc |
| ndc | package | 69911-765-85 | openfda.package_ndc |
| ndc | package | 69911-765-82 | openfda.package_ndc |
| ndc | package | 69911-874-01 | openfda.package_ndc |
| ndc | package | 69911-879-01 | openfda.package_ndc |
| ndc | package | 69911-864-02 | openfda.package_ndc |
| ndc | product | 69911-865 | openfda.product_ndc |
| ndc | product | 69911-867 | openfda.product_ndc |
| ndc | product | 69911-864 | openfda.product_ndc |
| ndc | product | 69911-866 | openfda.product_ndc |
| ndc | product | 69911-869 | openfda.product_ndc |
| ndc11 | package | 69911086602 | derived:openfda.package_ndc |
| ndc11 | package | 69911086702 | derived:openfda.package_ndc |
| ndc11 | package | 69911086402 | derived:openfda.package_ndc |
| ndc11 | package | 69911076582 | derived:openfda.package_ndc |
| ndc11 | package | 69911087401 | derived:openfda.package_ndc |
| ndc11 | package | 69911086902 | derived:openfda.package_ndc |
| ndc11 | package | 69911076585 | derived:openfda.package_ndc |
| ndc11 | package | 69911087901 | derived:openfda.package_ndc |
| ndc11 | package | 69911087701 | derived:openfda.package_ndc |
| ndc11 | package | 69911087601 | derived:openfda.package_ndc |
| ndc11 | package | 69911087501 | derived:openfda.package_ndc |
| ndc11 | package | 69911086502 | derived:openfda.package_ndc |
| rxcui | 1743994 | openfda.rxcui | |
| rxcui | 1743999 | openfda.rxcui | |
| spl id | fc29c907-a767-4a0e-b077-8c197e7ce8b3 | id | |
| spl set id | f74301bf-95e2-44ab-a8b6-98aa07b04683 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity have been reported. Should symptoms of hypersensitivity reactions including anaphylaxis occur, discontinue IDELVION and administer appropriate treatment. ( 5.1 ) The formation of neutralizing antibodies (inhibitors) to Factor IX has been reported with IDELVION. If expected Factor IX plasma recovery in patient plasma is not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor IX inhibitor concentration. ( 5.2 , 5.5 ) Thromboembolism (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis) may occur when using Factor IX-containing products. ( 5.3 ) Nephrotic syndrome has been reported following immune tolerance induction with Factor IX-containing products in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. ( 5.4 ) Factor IX activity assay results may vary with the type of activated partial thromboplastin time reagent used. ( 5.5 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions have occurred. Early signs of hypersensitivity reactions, which can progress to anaphylaxis include angioedema, chest tightness, hypotension, generalized urticaria, wheezing, and dyspnea. If symptoms of hypersensitivity or anaphylaxis occur, immediately discontinue administration and initiate appropriate treatment. IDELVION contains trace amounts of Chinese hamster ovary (CHO) proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. 5.2 Neutralizing Antibodies The formation of neutralizing antibodies (inhibitors) to Factor IX has been reported with IDELVION [see Adverse Reactions (6.3) ] . Monitor all patients treated with IDELVION for the development of neutralizing antibodies (inhibitors) by appropriate clinical observations or laboratory tests. Perform an assay that measures Factor IX inhibitor concentration if expected plasma Factor IX activity levels are not attained, or if the bleeding is not controlled with an appropriate dose. Patients with Factor IX inhibitors are at an increased risk of severe hypersensitivity reactions or anaphylaxis if re-exposed to Factor IX. Evaluate patients experiencing allergic reactions for the presence of an inhibitor and closely monitor patients with inhibitors for signs and symptoms of acute hypersensitivity reactions, particularly during early phases of exposure to the product [see Warnings and Precautions (5.1) ] . 5.3 Thromboembolic Complications Thromboembolism (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis) may occur when using Factor IX-containing products. Because of the potential risk for thromboembolism with the use of Factor IX products, monitor for early signs of thromboembolism and consumptive coagulopathy when administering IDELVION to patients with liver disease, fibrinolysis, perioperative status, or risk factors for thromboembolic events or disseminated intravascular coagulation. 5.4 Nephrotic Syndrome Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions. The safety and efficacy of using IDELVION for immune tolerance induction have not been established. 5.5 Monitoring Laboratory Tests Monitor Factor IX plasma levels by a one-stage clotting assay to confirm that adequate Factor IX levels have been achieved and maintained [see Dosage and Administration (2.1) ] . Factor IX activity assay results may vary with the type of activated partial thromboplastin time (aPTT) reagent used in the assay system. 1 For example, kaolin-based aPTT reagents along with other reagents designed to exhibit low responsiveness to lupus anticoagulant 2 have been shown to result in approximately 50% lower than expected recovery based on labeled potency. Consistent with similar findings for other recombinant Factor IX products, overestimation of Factor IX activity in spiked samples of IDELVION (mean overestimation 32%) occurred at low Factor IX levels with commonly used aPTT reagents. 3 Monitor patients for the development of inhibitors if expected Factor IX activity plasma levels are not attained, or if bleeding is not controlled with the recommended dose of IDELVION. Assays used to determine if a Factor IX inhibitor is present should be titered in Bethesda Units (BUs).
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (incidence ≥1%) reported in clinical trials were headache, dizziness, hypersensitivity and rash. The most common adverse reactions (incidence ≥1%) reported in clinical trials were headache, dizziness, hypersensitivity and rash. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. In five multicenter, prospective, open-label clinical trials with IDELVION, 114 previously treated patients (PTPs; exposed to a Factor IX-containing product for ≥100 exposure days (EDs)) received at least one infusion of IDELVION as part of on-demand treatment of bleeding episodes, perioperative management of major and minor surgical, dental, or other invasive procedures, routine prophylaxis, or pharmacokinetic evaluation. Twenty-seven children were <12 years of age, 9 adolescents were 12 to <18 years of age, and 78 adults were ≥18 to ≤65 years of age. A total of 16,326 injections were administered over a median of 1,543.5 days (range: 25 to 2,565 days). Adverse reactions that occurred in >0.5% of subjects are listed in Table 3. Table 3. Summary of Adverse Reactions in Previously Treated Patients MedDRA Standard System Organ Class Adverse Reaction Number of subjects n (%), (N=114) Nervous system disorders Headache 2 (1.8) Dizziness 2 (1.8) Immune system disorders Hypersensitivity 1 (0.9) Skin and subcutaneous tissue disorders Rash 1 (0.9) Eczema 1 (0.9) Safety of IDELVION was also evaluated in a completed study with 12 previously untreated patients (PUPs). The median number of EDs was 50 (range: 22 to 146) per subject, a total of 8 subjects achieved at least 50 EDs, of whom 3 subjects achieved ≥100 EDs. Adverse drug reactions were reported in 2 of 12 subjects treated with IDELVION. One subject (8.3%) in the PUP study developed a high titer of factor IX inhibitors (peak titer 188 BU/mL) and the same subject (8.3%) developed hypersensitivity. One additional subject (8.3%) in the PUP study developed rash. 6.2 Immunogenicity All subjects were monitored for inhibitory and binding antibodies to rIX-FP (specifically rFIX, pdFIX and albumin), and binding antibodies to CHO host cell proteins at the following time points: at screening, at 2-4 weeks, 12 weeks following the first infusion of IDELVION, every 3 months thereafter (every 6 months for binding antibodies in children). No subjects developed non-neutralizing antibodies against factor IX, or antibodies to albumin and CHO protein at any of the time points following infusion of IDELVION. One case of inhibitor development to Factor IX was reported in the clinical study which evaluated previously untreated patients. No antibodies to Factor IX have been observed in IDELVION clinical trials which enrolled previously treated patients. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, it may be misleading to compare the incidence of antibodies to IDELVION in the studies described above with the incidence of antibodies in other studies or to other products. 6.3 Postmarketing Experience The following adverse reaction has been identified during post-approval use of IDELVION. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Factor IX inhibitor development
adverse reactions table
<table width="100%" ID="table3"><caption>Table 3. Summary of Adverse Reactions in Previously Treated Patients</caption><col width="45%" align="left" valign="top"/><col width="25%" align="left" valign="top"/><col width="30%" align="left" valign="top"/><thead><tr><th styleCode="Lrule Rrule">MedDRA Standard System Organ Class</th><th styleCode="Rrule">Adverse Reaction</th><th styleCode="Rrule" align="center">Number of subjects n (%), (N=114)</th></tr></thead><tbody><tr><td styleCode="Lrule Rrule"><content styleCode="bold">Nervous system disorders</content></td><td styleCode="Rrule">Headache</td><td styleCode="Rrule">2 (1.8)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">Dizziness</td><td styleCode="Rrule">2 (1.8)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Immune system disorders</content></td><td styleCode="Rrule">Hypersensitivity</td><td styleCode="Rrule">1 (0.9)</td></tr><tr><td styleCode="Lrule Rrule"><content styleCode="bold">Skin and subcutaneous tissue disorders</content></td><td styleCode="Rrule">Rash</td><td styleCode="Rrule">1 (0.9)</td></tr><tr><td styleCode="Lrule Rrule"/><td styleCode="Rrule">Eczema</td><td styleCode="Rrule">1 (0.9)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.